Alan Yaghoubian, MD
Urology · Valencia, CANPI 1922481167
Payments from drug & device makers
Across 41 payments — averaging $801.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$32K
- Olympus America Inc.$173
- Cook Medical LLC$132
- Bayer$123
- Novo Nordisk Health Care AG$114
- Calyxo, Inc.$37
- plus $59 from 3 others
What the payments were for
- Grants$30,00091%
- Food & beverage$2,8409%
- Education$330%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 32 | $32,234 |
| Olympus America Inc. | 2 | $173 |
| Cook Medical LLC | 1 | $132 |
| Bayer | 1 | $123 |
| Novo Nordisk Health Care AG | 1 | $114 |
| Calyxo, Inc. | 1 | $37 |
| Alnylam Pharmaceuticals Inc. | 1 | $26 |
| Vertex | 1 | $19 |
| Novo Nordisk | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENERAL KIDNEY STONE DISEASE$30,136
- LITHOCLAST$245
- Moses$135
- Moses 550 DFL$134
- Soltive$133
- LITHO 150$132
- Nubeqa$123
How this compares
$32,872 in reported general payments places this provider in the 85th percentile of 1,324 urology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 14 | $17,917 |
| Tolterodine Tartrate ErTolterodine Tartrate | 41 | $8,403 |
| Potassium Citrate ErPotassium Citrate | 44 | $6,083 |
| Methenamine Hippurate | 37 | $3,156 |
| Tamsulosin Hcl | 113 | $1,282 |
| Cefpodoxime Proxetil | 38 | $1,133 |
| Finasteride | 59 | $942 |
| Chlorthalidone | 33 | $882 |
| Estradiol | 17 | $861 |
| Oxybutynin Chloride ErOxybutynin Chloride | 26 | $667 |
| Ciprofloxacin Hcl | 30 | $259 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 27 | $210 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 13 | $206 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 28 | $130 |
| Cephalexin | 15 | $95 |
Paid to pharmacies, not to this prescriber.
Other urology in Valencia
- Edward UchioOrange$21.1M
- Stephen FreedlandWest Hollywood$16.7M
- Alec KooTorrance$7.4M
- Karim ChamieLos Angeles$4.3M
- Ralph ClaymanOrange$3.9M
- Siamak DaneshmandLos Angeles$3.5M
- Arnold ChinLos Angeles$3.5M
- Roger LiLoma Linda$2.3M
- John KowalczykLos Angeles$1.8M
- Arie BelldegrunLos Angeles$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.